There are more than 650 active traditional ADC drugs currently, with only 14 having been approved to enter the market, and nearly 200 products still in different clinical research stages. Among them,Read More…
Bayer and Bicycle Therapeutics announced a strategic partnership agreement to develop, manufacture and commercialize targeted radiation conjugate drugs in the field of oncology using Bicycle Therapeutics’s synthetic peptide technology. Targeted radiotherapy isRead More…
Recently, Pfizer announced that it would buy Seagen for $229 a share in cash, for a total price of about $43 billion. According to the company’s website, Seagen currently has three ADCRead More…
Receptor-mediated Uptake Mechanism The target-dependent uptake and toxicity of ADC can also be mediated by different receptors that recognize the Fc (fragment crystallization) region of the IgG part of ADC. The constantRead More…
Nonspecific endocytosis Endocytosis is an important process in cell uptake of nutrients, regulation of transmembrane kinetics, synaptic vesicle recycling, and so on. Endocytosis can also play an important role in the uptakeRead More…
Linker-Unstable Payload Connection Connector-payload instability can cause the payload to be released prematurely into the bloodstream and lead to ADC miss toxicity. The choice of connectors is one of the main driversRead More…
So far, a total of 16 ADC drugs have been approved worldwide, and one (trastuzumab duocarmazine) is still in the stage of applying for listing. In recent years, with the significant increaseRead More…
Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…
Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…
Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…